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Until research proves otherwise,
keep revaccinating high-risk patients
It is unfortunate that we lack any clinical
data for or against pneumococcal revacci-
nation. As a result, we may disagree on the
correct revaccination schedule. Several
questions arise from this uncertainty. First,
do increasing antibody levels increase or
prolong immunity? Second, how do we
weigh the estimated numbers needed to
treat (NNT) versus the numbers needed to
harm (NNH)? And third, considering the
prevalence and severity of the disease,
should we err on the side of immunizing
more rather than less? Since booster shots
seem to be safe (implying a high NNH), the
ACIP guideline is probably a good 
compromise between increasing antibody
titers (theoretical benefit), and lack of 
efficacy data. Until we have further 
information to the contrary, I’m going to
continue to revaccinate high-risk patients.
Richard Kim, MD
Glendale, Ariz
C L I N I C A L C O M M E N TA R Y
E V I D E N C E - B A S E D A N S W E R
No patient-oriented evidence supports
pneumococcal revaccination of any patient
(high-risk or otherwise). Antibody levels may
be augmented by revaccination; however,
the clinical efficacy of revaccination, even
among high-risk patients, is unknown.
Revaccination is recommended by the
Advisory Committee on Immunization
Practices (ACIP) in certain circumstances.
(strength of recommendation [SOR]: C,
expert opinion based on physiology/bench
research). Revaccination once appears to be
safe, especially if provided 5 years or more
after primary vaccination (SOR: B, based
upon consistent results of cohort studies
and nonrandomized prospective trials).
z Evidence summary
Streptococcus pneumoniae is the most
common cause of community-acquired
pneumonia and the second most common
cause of bacterial meningitis in the United
States.1 An estimated 40,000 people die
annually in the US from pneumococcal
infections.1 Even with antibiotic treatment
and intensive care unit support, the mortal-
ity of patients with pneumococcal bac-
teremia approaches 25% to 30%.1
Because of the importance of this
pathogen, it has been the focus of several
trials to demonstrate the efficacy of the pri-
mary vaccination. To date, 7 meta-analyses
have been completed to assess the efficacy
of pneumococcal vaccine in adults, with
varying results.2–7 Most recently, a
Cochrane Review (updated in 2005)8 con-
cluded that “the combined results from
randomized studies fail to show that the
polysaccharide vaccine is effective in pre-
venting either pneumonia or death.”
However, they did recognize that the non-
randomized studies have consistently
shown that the polysaccharide vaccine is
effective in reducing the more specific out-
come of invasive pneumococcal disease
(bacteremia and meningitis). 
Multiple studies have used measure-
ment of antibody levels to assess the
response of patients to the vaccine and
for justification of the need for revaccina-
tion. However, measurement of antibody
levels to pneumococcal serotypes is diffi-
cult, inexact, and is only a surrogate
marker for the immune status of a
patient, which also relies on the overall
function of their immune system.
Although pneumococcal vaccine is most
highly recommended in patients with
chronic disease or immunodeficiency,
these patients have a poorer initial
response rate and a faster decline in 
antibody levels than younger, immuno-
competent recipients of the vaccine.1,9
A study of pneumococcal strains cul-
tured from hospitalized patients demon-
strated a duration of protection against
pneumococcal infection that was much
longer than that predicted by the shorter
duration of antibody levels. The vaccine’s
ability to reduce infection (due to serotypes
included in the vaccine) lasted for at least 9
years and overall efficacy for preventing
infection caused by the serotypes included
in the vaccine was 57%.1
Revaccination is safe; particularly
when performed more than 5 years after
the initial vaccination. Injection site reac-
tions are more common and more severe
in revaccinated persons (rising from 3%
to 15% in the immunocompetent
patient).10 Revaccination, however, does
not result in increased rates of hospital-
ization, and few severe reactions have
been reported.11
No randomized or prospective trials
regarding the clinical efficacy of revaccina-
tion have been completed. However, when
reviewing the studies of antibody response,
several summary conclusions can be made.
Among those who were nonresponders to
the initial vaccination, revaccination (even
repeated revaccination) is not effective in
stimulating any significant antibody
response.12–14 Among those who responded
to the primary vaccination, revaccination
can stimulate a second antibody
response—albeit to lower levels and with
less duration than after the initial vaccina-
tion.13,15–17 Among those who do respond to
revaccination, antibody levels can rapidly
decline to undetectable levels in a matter of
months, and they may or may not retain
protection against disease over time.14,15 It
appears that revaccination recommenda-
tions have been based on the safety of the
vaccination, concern for patients at risk
and reduced antibody levels, rather than
on proven clinical utility.
Recommendations from others
The Advisory Committee on Immuni-
zation Practices (ACIP) advises that the
vaccine be used in “persons with diseases
and other conditions predisposing to the
development of bacteremic pneumococcal
pneumonia” and that “revaccination
should not be done at intervals less than
five years.” They state "the value of vacci-
nation on the basis of advanced age is not
clear at this time.” (Further details may 
be found at: www.aafp.org/PreBuilt/
agecharts_adultimmunization.pdf.)
The American Academy of Family
Physicians, American College of
Physicians, the American College of
Obstetricians and Gynecologists and the
American Diabetes Association follow the
ACIP recommendations. 
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